

Independent Auditor's Review Report on Review of Quarter and Nine Months Unaudited Standalone Financial Results of Artemis Medicare Services Limited Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To  
The Board of Directors  
Artemis Medicare Services Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Artemis Medicare Services Limited** ('the Company') for the quarter and nine months ended December 31, 2025, (hereinafter referred to as "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended to date ("Listing Regulations").
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the *Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity'*, issued by the Institute of Chartered Accountants of India (ICAI). This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in all material respects in accordance with applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For T R Chadha & Co LLP  
Chartered Accountants  
Firm Registration No.006711N/N500028

Place of signature: Noida  
Date: February 02, 2026  
UDIN: 26057986VIYYTJ5369



  
Neena Goel  
Partner  
Membership No. 057986

**ARTEMIS MEDICARE SERVICES LIMITED**

CIN: L85110DL2004PLC126414

Registered office: Plot No.14, Sector 20, Dwarka, South West Delhi, Delhi- 110075

Ph.: +91-124-4511111; Email: investor@artemishospitals.com; Website: www.artemishospitals.com

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

(₹ in Lacs)

S No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25
		(Unaudited)					
<b>1.</b>	<b>Income</b>						
	(a) Revenue from Operations	26,712.34	26,978.31	22,689.34	78,670.51	67,846.00	91,326.13
	(b) Other Income	748.80	778.35	880.34	2,222.91	2,068.20	3,291.50
	<b>Total Income</b>	<b>27,461.14</b>	<b>27,756.66</b>	<b>23,569.68</b>	<b>80,893.42</b>	<b>69,914.20</b>	<b>94,617.63</b>
<b>2.</b>	<b>Expenses</b>						
	(a) Operative Expenses	16,341.97	16,285.91	13,731.31	48,072.44	40,862.32	55,160.06
	(b) Purchases of Stock in Trade	-	-	-	-	-	-
	(c) Changes in inventories of Stock in Trade	-	-	-	-	0.54	0.54
	(d) Employee Benefits Expense	4,231.24	3,825.42	3,634.90	11,787.31	10,571.07	14,371.00
	(e) Finance Costs	659.39	693.42	765.42	2,063.73	2,295.44	3,048.26
	(f) Depreciation and Amortization Expense	1,204.62	1,123.89	1,094.38	3,394.50	3,176.98	4,301.80
	(g) Other Expenses	1,759.27	1,851.15	1,639.55	5,327.21	4,982.11	6,810.51
	<b>Total Expenses</b>	<b>24,196.49</b>	<b>23,779.79</b>	<b>20,865.56</b>	<b>70,645.19</b>	<b>61,888.46</b>	<b>83,692.17</b>
<b>3.</b>	<b>Profit before exceptional items and tax (1-2)</b>	<b>3,264.65</b>	<b>3,976.87</b>	<b>2,704.12</b>	<b>10,248.23</b>	<b>8,025.74</b>	<b>10,925.46</b>
<b>4.</b>	<b>Exceptional items (Impact of Labour Code)</b>	<b>307.44</b>	<b>-</b>	<b>-</b>	<b>307.44</b>	<b>-</b>	<b>-</b>
<b>5.</b>	<b>Profit before tax (3-4)</b>	<b>2,957.21</b>	<b>3,976.87</b>	<b>2,704.12</b>	<b>9,940.79</b>	<b>8,025.74</b>	<b>10,925.46</b>
<b>6.</b>	<b>Tax Expense:</b>						
	(a) Current Tax	647.75	821.67	591.39	2,142.24	1,755.23	2,111.26
	(b) Earlier Year Tax	-	-	-	-	-	20.96
	(c) Deferred Tax Charge / (Credit)	58.18	158.75	34.90	409.10	245.19	447.46
	<b>Total Tax Expense</b>	<b>705.93</b>	<b>980.42</b>	<b>626.29</b>	<b>2,551.34</b>	<b>2,000.42</b>	<b>2,579.68</b>
<b>7.</b>	<b>Net Profit after tax (5-6)</b>	<b>2,251.28</b>	<b>2,996.45</b>	<b>2,077.83</b>	<b>7,389.45</b>	<b>6,025.32</b>	<b>8,345.78</b>
<b>8.</b>	<b>Other comprehensive income / (Loss)</b>						
	<b>Items that will not be reclassified to profit or loss</b>						
	(a) Remeasurement gain/(loss) of defined employee benefit plans	(58.55)	(28.61)	(43.05)	(106.95)	(129.16)	(79.15)
	(b) Income Tax relating to items that will not be reclassified to profit or loss	14.74	7.20	10.84	26.92	32.51	19.92
	(c) Deferred Tax adjustment on revaluation that will not be reclassified to profit or loss	11.02	11.01	12.71	33.04	38.12	50.83
	<b>Net Other comprehensive income / (Loss)</b>	<b>(32.79)</b>	<b>(10.40)</b>	<b>(19.50)</b>	<b>(46.99)</b>	<b>(58.53)</b>	<b>(8.40)</b>
<b>9.</b>	<b>Total comprehensive income (7+8)</b>	<b>2,218.49</b>	<b>2,986.05</b>	<b>2,058.33</b>	<b>7,342.46</b>	<b>5,966.79</b>	<b>8,337.38</b>
<b>10.</b>	<b>Paid up Equity Share Capital (Face value Re. 1/- each)</b>	<b>1,583.06</b>	<b>1,389.32</b>	<b>1,376.02</b>	<b>1,583.06</b>	<b>1,376.02</b>	<b>1,376.02</b>
<b>11.</b>	<b>Other Equity (Excluding Revaluation Reserves)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>75,954.72</b>
<b>12.</b>	<b>Earning per Equity Share (Face value Re. 1/- each)</b>						
	(a) Basic	1.42*	1.90*	1.33*	4.68*	3.94*	5.42
	(b) Diluted	1.42*	1.89*	1.31*	4.68*	3.89*	5.36

\* Not annualised



*Omkar Kaumar*

**Notes:-**

1. The above unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (financial results) have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on February 02, 2026. The financial results were subject to limited review by the statutory auditors, T R Chadha & Co LLP and the review report is unmodified.

2. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015, as amended (Ind AS), as prescribed under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and the other recognised accounting practices and policies to the extent applicable and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

**3. Segment Reporting:**

The Company's operation predominantly comprises providing Healthcare services to patients. As per Ind AS 108 and our internal structure and information mechanisms, the Company has only one reportable business segment, i.e., "Healthcare Services".

Geographical information

Geographical information analyses the Company's revenue by the country of domicile (i.e. India) and other countries. In presenting the geographical information, segment revenue has been based on the geographical location of the customers.

Region	Revenue from Operations					
	Quarter ended		Nine Months ended		Year ended	
	31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25
India	17,962.42	18,729.59	16,202.61	54,628.65	49,660.36	65,893.47
Outside India	8,749.92	8,248.72	6,486.73	24,041.86	18,185.64	25,432.66
<b>Total</b>	<b>26,712.34</b>	<b>26,978.31</b>	<b>22,689.34</b>	<b>78,670.51</b>	<b>67,846.00</b>	<b>91,326.13</b>

  

Region	Carrying amount of Non-Current Assets					
	Quarter ended		Nine Months ended		Year ended	
	31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25
India	84,558.23	82,735.49	79,241.29	84,558.23	79,241.29	79,363.07
Outside India	-	-	-	-	-	-
<b>Total</b>	<b>84,558.23</b>	<b>82,735.49</b>	<b>79,241.29</b>	<b>84,558.23</b>	<b>79,241.29</b>	<b>79,363.07</b>

4. During the quarter and nine months ended December 31, 2025, the Company has issued 4,11,750 and 17,41,750 number of equity shares, each fully paid up at ₹1/- per share to its Managing Director pursuant to Artemis Medicare Management Stock Option Plan – 2021 (the Plan), which have been duly listed in the respective Stock Exchanges, ranking pari passu with the existing equity shares of the Company.

5. On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty-nine existing labour laws into a unified framework governing employee benefits during employment and post-employment. The Labour Codes, amongst other things introduces changes, including a uniform definition of wages and enhanced benefits relating to leave. The Company has assessed the financial implications of these changes on the basis of best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India, which has resulted in increase in gratuity & leave liability by ₹307.44 Lacs. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Company has presented this incremental amount as "Impact of Labour Codes" under "Exceptional Item" in the Condensed Standalone Statement of Profit and Loss for the quarter and nine months ended December 31, 2025. The Company continues to monitor the developments pertaining to Labour Codes and will evaluate impact if any on the measurement of the employee benefits liability.

6. The previous period's/year's figures have been regrouped/reclassified wherever necessary to correspond with the current period/year classification/disclosures.

For and on behalf of the Board of Directors of  
Artemis Medicare Services Limited

*Ankur Kanwar*

Ankur Kanwar  
Chairman



Place : Gurugram  
Date : February 02, 2026



Independent Auditor's Review Report on Review of Quarter and nine months Unaudited Consolidated Unaudited Financial Results of Artemis Medicare Services Limited Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To  
The Board of Directors  
Artemis Medicare Services Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Artemis Medicare Services Limited** ('the Holding Company') and its subsidiary (the holding Company and its subsidiary together referred to as 'the Group') for the quarter and nine months ended December 31, 2025, (hereinafter referred to as "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended to date ("Listing Regulations").
2. The Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the *Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity'*, issued by the Institute of Chartered Accountants of India (ICAI). This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with circular issued by the SEBI under Regulations 33(8) of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
  - a. Artemis Medicare Services Limited, the Holding Company
  - b. Artemis Cardiac Care Private Limited, a Subsidiary Company
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Consolidated Statement prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of Listing Regulations (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.



T R Chadha & Co LLP, A limited liability partnership with LLP Identification No. AAF-3926

Noida Branch Office: Plot No. B-13, First Floor, Sector-1, Noida- 201301, Gautam Budh Nagar (U.P.) Ph: +91 120 4499900 E-mail: [noida@trchadha.com](mailto:noida@trchadha.com)

Corporate/ Regd. Office: B-30, Connaught Place, Kuthiala Building, New Delhi - 110001 Ph: +91 011 43259900 E-mail: [delhi@trchadha.com](mailto:delhi@trchadha.com)

Offices: Ahmedabad | Bengaluru | Chennai | Gurugram | Hyderabad | Mumbai | New Delhi | Noida | Pune | Tirupati | Vadodara

[www.trchadha.com](http://www.trchadha.com)

### Other Matters

6. The accompanying Statements include the unaudited interim financial results/ statement and other financial information, in respect of the subsidiary company i.e., Artemis Cardiac Care Private Limited, whose unaudited interim financial results/ statements include total revenue of ₹522.51 lakhs and ₹1530.71 lakhs, total Net Profit/(loss) after Tax of ₹(30.11) lakhs and ₹(43.78) lakhs, total comprehensive income/(loss) of ₹(30.96) lakhs and ₹ (45.35) lakhs, for the quarter and nine months ended on December 31, 2025, as considered in the Statement.

These interim financial statements and other financial information have been reviewed by another firm of Chartered Accountants whose Review Report, vide which they have issued an unmodified conclusion, have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of such other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in this matter.

For T R Chadha & Co LLP  
Chartered Accountants  
Firm Registration No.006711N/N500028



Place of Signature: Noida  
Date: February 02, 2026  
UDIN: 26057986ZJLGSA3011

Neena Goel  
Partner  
Membership No. 057986

**ARTEMIS MEDICARE SERVICES LIMITED**

CIN: L85110DL2004PLC126414

Registered office: Plot No.14, Sector 20, Dwarka, South West Delhi, Delhi- 110075

Ph.: +91-124-4511111; Email: investor@artemishospitals.com; Website: www.artemishospitals.com

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

(₹ in Lacs)

S No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25
		(Unaudited)					(Audited)
<b>1.</b>	<b>Income</b>						
	(a) Revenue from Operations	27,235.23	27,470.28	23,239.14	80,201.60	69,701.66	93,691.67
	(b) Other Income	746.01	765.44	879.75	2,204.24	2,064.09	3,298.59
	<b>Total Income</b>	<b>27,981.24</b>	<b>28,235.72</b>	<b>24,118.89</b>	<b>82,405.84</b>	<b>71,765.75</b>	<b>96,990.26</b>
<b>2.</b>	<b>Expenses</b>						
	(a) Operative Expenses	16,611.56	16,546.67	14,044.25	48,884.96	41,929.58	56,521.05
	(b) Purchases of Stock in Trade	-	-	-	-	-	-
	(c) Changes in inventories of Stock in Trade	-	-	-	-	0.54	0.54
	(d) Employee Benefits Expense	4,342.42	3,927.46	3,747.14	12,109.97	10,922.96	14,837.26
	(e) Finance Costs	674.59	718.58	800.18	2,131.35	2,411.26	3,194.48
	(f) Depreciation and Amortization Expense	1,244.34	1,171.16	1,145.04	3,531.13	3,342.21	4,516.49
	(g) Other Expenses	1,824.37	1,934.27	1,701.39	5,548.45	5,259.04	7,153.86
	<b>Total Expenses</b>	<b>24,697.28</b>	<b>24,298.14</b>	<b>21,438.00</b>	<b>72,205.86</b>	<b>63,865.59</b>	<b>86,223.68</b>
<b>3.</b>	<b>Profit before exceptional items and tax (1-2)</b>	<b>3,283.96</b>	<b>3,937.58</b>	<b>2,680.89</b>	<b>10,199.98</b>	<b>7,900.16</b>	<b>10,766.58</b>
<b>4.</b>	<b>Exceptional Items (Impact of Labour Code)</b>	<b>307.44</b>	<b>-</b>	<b>-</b>	<b>307.44</b>	<b>-</b>	<b>-</b>
<b>5.</b>	<b>Profit before tax (3-4)</b>	<b>2,976.52</b>	<b>3,937.58</b>	<b>2,680.89</b>	<b>9,892.54</b>	<b>7,900.16</b>	<b>10,766.58</b>
<b>6.</b>	<b>Tax Expense:</b>						
	(a) Current Tax	647.75	821.67	591.39	2,142.24	1,755.23	2,111.26
	(b) Earlier Year Tax	-	-	-	-	-	20.96
	(c) Deferred Tax Charge / (Credit)	105.33	115.69	29.77	406.89	219.70	416.74
	<b>Total Tax Expense</b>	<b>753.08</b>	<b>937.36</b>	<b>621.16</b>	<b>2,549.13</b>	<b>1,974.93</b>	<b>2,548.96</b>
<b>7.</b>	<b>Net Profit after tax (5-6)</b>	<b>2,223.44</b>	<b>3,000.22</b>	<b>2,059.73</b>	<b>7,343.41</b>	<b>5,925.23</b>	<b>8,217.62</b>
<b>8.</b>	<b>Other comprehensive income / (Loss)</b>						
	<b>Items that will not be reclassified to profit or loss</b>						
	(a) Remeasurement gain/(loss) of defined employee benefit plans	(59.69)	(29.10)	(43.73)	(109.06)	(131.19)	(81.08)
	(b) Income Tax relating to items that will not be reclassified to profit or loss	15.03	7.33	11.01	27.46	33.02	20.41
	(c) Deferred Tax adjustment on revaluation that will not be reclassified to profit or loss	11.02	11.01	12.71	33.04	38.12	50.83
	<b>Net Other comprehensive income / (Loss)</b>	<b>(33.64)</b>	<b>(10.76)</b>	<b>(20.01)</b>	<b>(48.56)</b>	<b>(60.05)</b>	<b>(9.84)</b>
<b>9.</b>	<b>Total comprehensive income (7+8)</b>	<b>2,189.81</b>	<b>2,989.46</b>	<b>2,039.72</b>	<b>7,294.86</b>	<b>5,865.18</b>	<b>8,207.78</b>
<b>10.</b>	<b>Profit / (Loss) attributable to :</b>						
	Shareholders of the Company	2,233.99	2,996.88	2,066.79	7,358.74	5,959.68	8,262.58
	Non-Controlling Interest	(10.54)	3.35	(7.05)	(15.32)	(34.45)	(44.96)
<b>11.</b>	<b>Total Comprehensive Income / (Loss) attributable to :</b>						
	Shareholders of the Company	2,200.64	2,986.24	2,046.94	7,310.72	5,900.16	8,253.24
	Non-Controlling Interest	(10.83)	3.22	(7.22)	(15.87)	(34.98)	(45.46)
<b>12.</b>	<b>Paid up Equity Share Capital (Face value Re. 1/- each)</b>	<b>1,583.06</b>	<b>1,389.32</b>	<b>1,376.02</b>	<b>1,583.06</b>	<b>1,376.02</b>	<b>1,376.02</b>
<b>13.</b>	<b>Other Equity (Excluding Revaluation Reserves)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>75,542.52</b>
<b>14.</b>	<b>Earning per Equity Share (Face value Re. 1/- each)</b>						
	(a) Basic	1.41*	1.90*	1.32*	4.66*	3.89*	5.37
	(b) Diluted	1.41*	1.89*	1.31*	4.66*	3.85*	5.31

\* Not annualised



*Anil Kumar*

**Notes:-**

1. The above unaudited Consolidated financial results of Artemis Medicare Services Limited (the Company) and one Subsidiary Company (together referred as 'the Group') for the quarter and nine months ended December 31, 2025, have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on February 02, 2026. The financial results were subject to limited review by the statutory auditors, T R Chadha & Co LLP and the review report is unmodified.

2. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015, as amended (Ind AS), as prescribed under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and the other recognised accounting practices and policies to the extent applicable and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

**3. Segment Reporting:**

The Group's operation predominantly comprises providing Healthcare services to patients. As per Ind AS 108 and our internal structure and information mechanisms, the Group has only one reportable business segment, i.e., "Healthcare Services".

**Geographical information**

Geographical information analyses the Group's revenue by the Group's country of domicile (i.e. India) and other countries. In presenting the geographical information, segment revenue has been based on the geographical location of the customers.

Region	Revenue from Operations					
	Quarter ended		Nine Months ended		Year ended	
	31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25
India	18,485.31	19,221.56	16,752.41	56,159.74	51,516.02	68,259.01
Outside India	8,749.92	8,248.72	6,486.73	24,041.86	18,135.64	25,432.66
<b>Total</b>	<b>27,235.23</b>	<b>27,470.28</b>	<b>23,239.14</b>	<b>80,201.60</b>	<b>69,701.66</b>	<b>93,691.67</b>

  

Region	Carrying amount of Non-Current Assets					
	Quarter ended		Nine Months ended		Year ended	
	31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Mar-25	
India	85,892.70	84,213.70	81,234.62	85,892.70	81,234.62	81,142.92
Outside India	-	-	-	-	-	-
<b>Total</b>	<b>85,892.70</b>	<b>84,213.70</b>	<b>81,234.62</b>	<b>85,892.70</b>	<b>81,234.62</b>	<b>81,142.92</b>

4. During the quarter and nine months ended December 31, 2025, the Parent Company has issued 4,11,750 and 17,41,750 number of equity shares, each fully paid up at ₹1/- per share to its Managing Director pursuant to Artemis Medicare Management Stock Option Plan – 2021 (the Plan), which have been duly listed in the respective Stock Exchanges, ranking pari passu with the existing equity shares of the parent Company.

5. On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty-nine existing labour laws into a unified framework governing employee benefits during employment and post-employment. The Labour Codes, amongst other things introduces changes, including a uniform definition of wages and enhanced benefits relating to leave. The Group has assessed the financial implications of these changes on the basis of best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India, which has resulted in increase in gratuity & leave liability by ₹307.44 Lacs. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Parent Company has presented this incremental amount as "Impact of Labour Codes" under "Exceptional Item" in the Condensed Consolidated Statement of Profit and Loss for the quarter and nine months ended December 31, 2025. The Parent Company continues to monitor the developments pertaining to Labour Codes and will evaluate impact if any on the measurement of the employee benefits liability.

6. The previous period's/year's figures have been regrouped/reclassified wherever necessary to correspond with the current period/year classification/disclosures.

For and on behalf of the Board of Directors of  
Artemis Medicare Services Limited



*Onkar Kanwar*

Onkar Kanwar  
Chairman

Place : Gurugram  
Date : February 02, 2026

